LINKING TARGETED CANCER THERAPY TO BETTER PATIENT OUTCOMES
ABOUT US
Spirea, a biotech company spun out from the University of Cambridge, is committed to delivering the next generation of antibody drug conjugate (ADC) therapeutics to revolutionise cancer treatment and improve the lives of patients.
OUR TECHNOLOGY
Antibody Drug Conjugates (ADCs) combine the cell killing activity of a cytotoxic drug payload with the targeting ability of an antibody.
​
Unlike classic chemotherapy that does not discriminate between cancer and healthy cells, ADCs are targeted to kill cancer cells only. They have the potential to reshape cancer treatment.
​
However, most current ADCs in development are limited by a lack of flexibility, toxic side-effects and limitations in the range of cancer patients that can be treated.
​
Spirea has developed an exciting and flexible new approach to building ADCs that allows more drug payload to be specifically directed to the tumour cell. This results in an increase in therapeutic effect whilst substantially reducing debilitating side-effects.
​
By delivering the right amount of the right drug to the right cells Spirea will unlock a new generation of accessible, powerful and well-tolerated medicines for the treatment of a wide range of cancers.
MEET THE TEAM
Myriam Ouberai is the Founder and Chief Executive Officer of Spirea. Myriam holds a PhD in Chemistry and has significant experience in drug delivery and biopharmaceuticals in both academia and industry. Prior to Spirea, Myriam was a Senior Postdoctoral Research Associate at the University of Cambridge, Nanoscience Centre. In 2018, Myriam was selected as one of 50 Movers and Shakers in BioBusiness by UK biotech platform BioBeat.
Adam Collier is the Head of Business Operations. Adam has over 15 years’ experience in biotech management, business development and early-stage company formation. He holds a PhD in Virology from the University of Bath and an MBA from the Judge Business School, Cambridge. He has held several senior business development and management positions at Medimmune, Ablynx and Isogenica, and was a Founder-Director of Horizon Discovery Ltd.
SUPPORTED BY
Spirea is supported by a number of successful, high-profile
board members from the life sciences:
Jane Dancer, Chair, former Chief Business Officer at F-star,
Gaynor Fryers, former Vice-President of Business Development at AstraZeneca,
Christine Martin, Deputy Head of Seed Funds at Cambridge Enterprise.
Spirea is also supported by the Healthcare Accelerator Start Codon and the Cambridge Judge Business School Entrepreneurship Centre's Accelerator, Accelerate Cambridge.
Spirea has received grant funding from Innovate UK and the Royal Society of Chemistry.




NEWS
GET IN TOUCH
We are always very interested in speaking with potential investors, partners and collaborators so please do get in touch.